Hemolytic–uremic syndrome, malignant hypertension and IgA nephropathy: Successful treatment with plasma exchange therapy

2012 ◽  
Vol 47 (2) ◽  
pp. 155-158 ◽  
Author(s):  
Chrysoula Pipili ◽  
Konstantinos Pantelias ◽  
Nikos Papaioannou ◽  
Helen Paraskevakou ◽  
Eirini Grapsa
Keyword(s):  
Hemolytic Uremic Syndrome ◽  
Plasma Exchange ◽  
Iga Nephropathy ◽  
Successful Treatment ◽  
Malignant Hypertension ◽  
Plasma Exchange Therapy ◽  
Uremic Syndrome

Postpartum atypical hemolytic uremic syndrome successfully treated with plasma exchange therapy: A case report

2015 ◽  
Vol 112 ◽  
pp. 140
Author(s):  
Masahiko Chiga ◽  
Munekage Yamaguchi ◽  
Yoshinori Okamura ◽  
Ritsuo Honda ◽  
Takashi Ohba ◽  
...  
Keyword(s):  
Case Report ◽  
Hemolytic Uremic Syndrome ◽  
Plasma Exchange ◽  
Atypical Hemolytic Uremic Syndrome ◽  
Plasma Exchange Therapy ◽  
Uremic Syndrome

scholarly journals Plasma exchange therapy for a boy with hemolytic-uremic syndrome

1982 ◽  
Vol 15 (6) ◽  
pp. 777-780
Author(s):  
Kazuo Tsuzuki ◽  
Shigeru Minowa ◽  
Norishi Ueda ◽  
Hiromichi Noguchi ◽  
Minoru Tanabe ◽  
...  
Keyword(s):  
Hemolytic Uremic Syndrome ◽  
Plasma Exchange ◽  
Plasma Exchange Therapy ◽  
Uremic Syndrome

scholarly journals Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Han-Mou Tsai ◽  
Elizabeth Kuo
Keyword(s):  
Renal Function ◽  
Platelet Count ◽  
Hemolytic Uremic Syndrome ◽  
Plasma Exchange ◽  
Complement Activation ◽  
Atypical Hemolytic Uremic Syndrome ◽  
Steady Increase ◽  
Platelet Counts ◽  
Plasma Exchange Therapy ◽  
Uremic Syndrome

Eculizumab is highly effective in controlling complement activation in patients with the atypical hemolytic uremic syndrome (aHUS). However, the course of responses to the treatment is not well understood. We reviewed the responses to eculizumab therapy for aHUS. The results show that, in patients with aHUS, eculizumab therapy, when not accompanied with concurrent plasma exchange therapy, led to steady increase in the platelet count and improvement in extra-renal complications within 3 days. By day 7, the platelet count was normal in 15 of 17 cases. The resolution of hemolytic anemia and improvement in renal function were less predictable and were not apparent for weeks to months in two patients. The swift response in the platelet counts was only observed in one of five cases who received concurrent plasma exchange therapy and was not observed in a case of TMA due to gemcitabine/carboplatin. In summary, eculizumab leads to rapid increase in the platelet counts and resolution of extrarenal symptoms in patients with aHUS. Concurrent plasma exchange greatly impedes the response of aHUS to eculizumab therapy. Eculizumab is ineffective for gemcitabine/carboplatin associated TMA.

Atypical Hemolytic Uremic Syndrome Associated with Complement Factor H Mutation and IgA Nephropathy: A Case Report Successfully Treated with Eculizumab

Nephron ◽  
2017 ◽  
Vol 138 (4) ◽  
pp. 324-327 ◽  
Author(s):  
Hironori Nakamura ◽  
Mariko Anayama ◽  
Mutsuki Makino ◽  
Yasushi Makino ◽  
Katsuhiko Tamura ◽  
...  
Keyword(s):  
Case Report ◽  
Hemolytic Uremic Syndrome ◽  
Iga Nephropathy ◽  
Atypical Hemolytic Uremic Syndrome ◽  
Factor H ◽  
Complement Factor H ◽  
Complement Factor ◽  
Uremic Syndrome ◽  
Factor H Mutation
Sign in / Sign up

Export Citation Format

Share Document